Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 trial of once-monthly oral islatravir for HIV pre-exposure prophylaxis
2020-003309-79Phase 3Completed
- Sponsor
- Merck & Co.
- Start
- Dec 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of islatravir in human immunodeficiency virus infection (HIV) (2 arms), sponsored by Merck & Co. Primary endpoint: Incidence rate per year of confirmed HIV-1 infection. Started Dec 2020; status: completed.
02
Drugs
islatravir
03
Conditions
human immunodeficiency virus infection (HIV)
Beyond the preview
Go deeper on 2020-003309-79.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2020-003309-79.